Annals of Surgical Oncology

, Volume 14, Issue 2, pp 484–492 | Cite as

A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei

  • Tristan D. Yan
  • Deborah Black
  • Renaldo Savady
  • Paul H. Sugarbaker



The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established.


Searches for all relevant studies prior to March 2006 were performed on six databases. Two reviewers independently appraised each study using a predetermined protocol. The quality of each study was assessed. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies.


Ten most recent updates from each institution were included for appraisal and data extraction. There were no randomized controlled trials or comparative studies. All included articles were observational studies without control groups. Five studies were relatively large series (n≥100). Two studies had relatively long-term follow-up (48 months and 52 months). The median follow-up in the remaining eight studies was shorter than 3 years (range 19–35 months). The median survival ranged from 51 to 156 months. The 1-, 2-, 3- and 5-year survival rates varied from 80 to 100%, 76 to 96%, 59 to 96% and 52 to 96%, respectively. The overall morbidity rate varied from 33 to 56%. The overall mortality rates ranged from 0 to 18%.


This study reviewed current evidence on CRS and PIC for PMP. Only observational studies were available for evaluation, which demonstrated some promising long-term results, as compared to historical controls. Due to the rarity of this disease, a well-designed prospective multi-institutional study would be meaningful.


Pseudomyxoma peritonei Cytoreductive surgery Intraperitoneal chemotherapy Appendiceal neoplasms Systematic review 



Tristan D. Yan, a surgical oncology research fellow, is supported by Foundation for Applied Research in Gastrointestinal Oncology and Medstar Research Institute.


  1. 1.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome. Lancet Oncol 2006;7:69–76PubMedCrossRefGoogle Scholar
  2. 2.
    Brendan MJ, Cecil TD. The etiology, clinical presentation and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 2003;12:585–603CrossRefGoogle Scholar
  3. 3.
    Carmignani P, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465–72PubMedCrossRefGoogle Scholar
  4. 4.
    Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112–9PubMedCrossRefGoogle Scholar
  5. 5.
    Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005;241:300–8PubMedCrossRefGoogle Scholar
  6. 6.
    Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous Neoplasms: A Clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089–103PubMedCrossRefGoogle Scholar
  7. 7.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42PubMedGoogle Scholar
  8. 8.
    Sugarbaker PH, Graves T, DeBruijn EA, et al. Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990;50:5790–4PubMedGoogle Scholar
  9. 9.
    Katz M, Barone R. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 2003;12:673–88PubMedCrossRefGoogle Scholar
  10. 10.
    Bryant J, Clegg AJ, Sidhu MK, et al. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg 2005;92:153–8PubMedCrossRefGoogle Scholar
  11. 11.
    Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol 1995;19:1390–408PubMedGoogle Scholar
  12. 12.
    NHS Centre for Reviews and Dissemination. Undertaking systemic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD report 4, 2nd ed. York: NHS Centre for Reviews and Dissemination; 2001Google Scholar
  13. 13.
    Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin—natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;50:772–9CrossRefGoogle Scholar
  14. 14.
    Sugarbaker PH. Curative treatment of peritoneal carcinomatosis from grade I mucinous adenocarcinoma. Surg Rounds 1988; 45–63Google Scholar
  15. 15.
    Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis. Cancer J Surg 1989;32:164–70Google Scholar
  16. 16.
    Sugarbaker PH, Cunliffe W, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83–97PubMedGoogle Scholar
  17. 17.
    Sugarbaker PH, Zhu BW, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323–9PubMedCrossRefGoogle Scholar
  18. 18.
    Fernandez-Trigo V, Shamsa F, Sugarbaker PH. Clinical determinants of treatment failures after cytoreductive surgery and intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Acta Chr Austriaca 1995;97–183Google Scholar
  19. 19.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMedGoogle Scholar
  20. 20.
    Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622–9PubMedCrossRefGoogle Scholar
  21. 21.
    Zoetmulder FAN, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Surg Oncol 1996; 32A:1727–33Google Scholar
  22. 22.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31PubMedCrossRefGoogle Scholar
  23. 23.
    Esquivel J, Sugarbaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg 2000;87:1414–8PubMedCrossRefGoogle Scholar
  24. 24.
    Esquivel J, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg 2001;234:198–205PubMedCrossRefGoogle Scholar
  25. 25.
    Yan H, Pestieau SR, Shmookler BM, et al. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. Mod Pathol 2001;14:164–71PubMedCrossRefGoogle Scholar
  26. 26.
    Ronett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85–91CrossRefGoogle Scholar
  27. 27.
    Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg 2002;89:208–12PubMedGoogle Scholar
  28. 28.
    Mohamed F, Gething S, Haiba M, et al. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004;86:10–15PubMedCrossRefGoogle Scholar
  29. 29.
    Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004;240:278–85PubMedCrossRefGoogle Scholar
  30. 30.
    Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004;91:304–11PubMedCrossRefGoogle Scholar
  31. 31.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006;13:1–11CrossRefGoogle Scholar
  32. 32.
    Witkamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458–63PubMedCrossRefGoogle Scholar
  33. 33.
    van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9:961–7PubMedCrossRefGoogle Scholar
  34. 34.
    van Ruth S, Acherman YIZ, van der Vijver MJ, et al. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 2003;29:682–8PubMedCrossRefGoogle Scholar
  35. 35.
    Smeenk RM, Verwaal VJ, Zoetmulder FAN. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol 2006;32:186–90PubMedCrossRefGoogle Scholar
  36. 36.
    Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic chemotherapy. Ann Surg, (in press)Google Scholar
  37. 37.
    Loggie BW, Fleming RA, Mcquellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561–8PubMedGoogle Scholar
  38. 38.
    McQuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73PubMedCrossRefGoogle Scholar
  39. 39.
    McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155–62PubMedCrossRefGoogle Scholar
  40. 40.
    Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:624–34PubMedCrossRefGoogle Scholar
  41. 41.
    Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001;27:286–90PubMedCrossRefGoogle Scholar
  42. 42.
    Guner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis 2005;20:155–60PubMedCrossRefGoogle Scholar
  43. 43.
    Deraco M, Gronchi A, Mazzaferro V, et al. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with pseudomyxoma peritonei. Tumori 2002;88:370–5PubMedGoogle Scholar
  44. 44.
    Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion: a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393–8PubMedCrossRefGoogle Scholar
  45. 45.
    Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799–806PubMedCrossRefGoogle Scholar
  46. 46.
    Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005;48:1372–9PubMedCrossRefGoogle Scholar
  47. 47.
    Butterworth SA, Panton NM, Klaassen DJ, et al. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg 2002;183:529–32PubMedCrossRefGoogle Scholar
  48. 48.
    Yan TD, Links M, Glenn D, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective analysis of 50 patients. Br J Surg 2006; 93:1270–6PubMedCrossRefGoogle Scholar
  49. 49.
    Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40:256–60PubMedGoogle Scholar
  50. 50.
    Armour EP, McEachern D, Wang Z, et al. Sensitivity of human cells to mild hyperthermia. Cancer Res 1993;53:2740–3744PubMedGoogle Scholar
  51. 51.
    Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100–4PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Tristan D. Yan
    • 1
  • Deborah Black
    • 2
  • Renaldo Savady
    • 1
  • Paul H. Sugarbaker
    • 1
  1. 1.Peritoneal Surface Malignancy ProgramWashington Cancer Institute, Washington Hospital CenterWashingtonUSA
  2. 2.School of Public Health and Community MedicineThe University of New South WalesSydneyAustralia

Personalised recommendations